Trending Topic

3 mins

Trending Topic

Developed by Touch
Mark CompleteCompleted
BookmarkBookmarked

We are delighted to present the latest edition of touchREVIEWS in Oncology & Haematology. This issue underscores the evolving landscape of cancer therapeutics, showcasing advances across a wide range of malignancies, from haematologic diseases to solid tumours, through novel mechanisms, emerging biomarkers and personalized treatment strategies. We begin with an editorial by Isabela Wen-Chi Chang […]

Evan Lipson, ASCO 2021: Relatlimab plus Nivolumab in Advanced Melanoma

Share
Facebook
X (formerly Twitter)
LinkedIn
Via Email
Mark CompleteCompleted
BookmarkBookmarked
Copy LinkLink Copied
Published Online: Jun 28th 2021

TouchONCOLOGY got the chance to catch up with Dr Evan Lipson (Johns Hopkins Sidney Kimmel Comprehensive Cancer Center, Baltimore, MD, USA) around the RELATIVITY-047 study, which investigated the combined therapy of relatlimab plus nivolumab in patients with advanced melanoma.

The abstract ‘Relatlimab (RELA) plus nivolumab (NIVO) versus NIVO in first-line advanced melanoma: Primary phase III results from RELATIVITY-047 (CA224-047)‘ (abstract number 9503) was presented at the 2021 ASCO Annual Meeting.

Questions

  1. Could you tell us a little about relatlimab, and the rationale for using it in combination with nivolumab in the treatment of advanced melanoma? (0:22)
  2. What were the aim, design and clinical endpoints of the RELATIVITY-047 study? (1:21)
  3. How well were survival and safety endpoints met? (2:38)
  4. Which subgroups were most likely to benefit from this combined therapy? (3:39)
  5. How do these findings compare with those of the Checkmate-067 study? (4:06)
  6. What were the conclusions from the study and how do the findings influence the future treatment landscape? (4:50)

Disclosures: Advisory Board (Personal): Bristol Myers-Squibb, Novartis, EMD Serono, Array BioPharma, Merck, Sanofi, Regeneron, Genentech, Odonate Therapeutics; Consultant/ Other (Personal): Macrogenics; Local PI (No financial interest, Institutional): Regeneron, Merck; Coordinating PI (No financial interest, Institutional): Bristol-Myers Squibb.

Support: Interview and filming supported by Touch Medical Media.

Filmed in coverage of the 2021 ASCO Annual Meeting.

Share
Facebook
X (formerly Twitter)
LinkedIn
Via Email
Mark CompleteCompleted
BookmarkBookmarked
Copy LinkLink Copied
Close Popup